Efficacy and safety of Le-Mai particle in patients with angina pectoris

Abstract

This study aimed to verify the efficacy and safety of the Le-Mai particle in patients with angina pectoris. Randomized controlled trials (RCTs) were searched from numerous databases. Clinical symptom improvement was served as the primary endpoint and electrocardiogram (ECG) improvement as the secondary endpoint to testify the efficacy of Le-Mai particle. The safety of Le-Mai particle was also evaluated. Six RCTs were included in our analyses. Two hundred and seventy-nine patients treated with Le-Mai particle in combination with conventional western medicine (CWM) and 278 patients treated with CWM alone were enrolled. Treatment with Le-Mai particle exhibited a better therapeutic effect on both angina symptom improvement (odds ratios [OR] = 3.85, 95% confidence intervals [CI] = 2.38–6.24,P < 0.00001) and ECG improvement (OR = 1.98, 95% CI = 1.38–2.85,P = 0.0002) as compared to the control group. When compared with CWM alone, no significant increase in the adverse reaction was observed in the Le-Mai group. The study provided preliminary evidence that complementary therapy with the Le-Mai particle is effective and safe in patients with angina pectoris.

Keywords

• Angina pectoris
• Le-Mai particle
• pooled analysis